|Abbreviated Mental Test Score (AMTS)
| Dementia with Lewy bodies
| Frontotemporal dementia
| Corticobasal degeneration
| Creutzfeldt Jakob disease
| Vascular Dementia
| Anti Dementia Drugs
| AIDS Dementia Complex
| Normal Pressure Hydrocephalus
| Acetylcholinesterase inhibitors
| Mental Capacity Act 2005
- Levels of evidence were rated using accepted standards which were then translated into grades of recommendation A to D
- A has the strongest evidence base (from RCTs) and D the weakest (case studies or expert opinion).
- Current clinical diagnostic criteria for dementia have sufficient accuracy to be applied in clinical practice (B)
- Both CT/MRI and functional (PET/SPECT) brain imaging can improve diagnostic accuracy, in particular, situations (B).
Mild to Moderate Alzheimer's disease
- Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are effective for cognition
Moderate to Severe Alzheimer's disease
- Memantine for moderate to severe Alzheimer's disease
- May be combined with Cholinesterase inhibitors
- Drugs should not be stopped just because dementia severity increases
No real evidence
- Statins, anti-inflammatory drugs, vitamin E, nutritional supplements and Ginkgo biloba for the treatment or prevention of Alzheimer disease (A).
- No drug use effective for those with mild cognitive
- Cholinesterase inhibitors are not effective and may cause agitation (A)
- Selective serotonin reuptake inhibitors may help behavioural (but not cognitive) features (B).
Lewy Body disease
- Cholinesterase inhibitors should be used for the treatment of people with Lewy body dementias (both Parkinson disease dementia and dementia with Lewy bodies)
- Memantine may be helpful (A).
- No drugs are clearly effective in vascular dementia
- Cholinesterase inhibitors are beneficial in mixed dementia (B).